Skip to main content
Premium Trial:

Request an Annual Quote

Trangenomic s Q4 Sales Decline 21 Percent As Net Loss Nearly Doubles

NEW YORK, March 17 (GenomeWeb News) - Transgenomic yesterday reported a 21.3-percent decrease in net sales and a greater net loss for the fourth quarter.

 

Sales for the three months ended Dec. 31, 2005, declined to $5.3 million from $6.8 million in the year-ago period.

 

The company's net loss for the fourth quarter almost doubled to $11.2 million, compared with $6.9 million in Q4 2005.

 

Transgenomic did not break out its R&D expenses.

 

As of Dec. 31, Transgenomic had $6.7 million in cash and cash equivalents.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.